Apixaban vs Rivaroxaban
Clinical Comparison
Clinical Context
Both apixaban and rivaroxaban are first-line DOACs for atrial fibrillation and VTE. NICE recommends either, but real-world prescribing often favours apixaban for its lower bleeding risk, while rivaroxaban's once-daily dosing suits patients where adherence to BD dosing is a concern.
Drug Profiles
Apixaban
Direct oral anticoagulant (DOAC) — Factor Xa inhibitor
Mechanism
Selective, reversible direct inhibitor of Factor Xa, blocking thrombin generation and clot formation
Indications
- Non-valvular atrial fibrillation (stroke prevention)
- Treatment and prevention of DVT/PE
- VTE prophylaxis after hip or knee replacement
Common Doses
AF: 5 mg BD (2.5 mg BD if meets dose-reduction criteria); VTE: 10 mg BD for 7 days then 5 mg BD
Route
Oral
Onset & Duration
Onset 3-4 hours; half-life 12 hours
Rivaroxaban
Direct oral anticoagulant (DOAC) — Factor Xa inhibitor
Mechanism
Selective, reversible direct inhibitor of Factor Xa with high oral bioavailability
Indications
- Non-valvular atrial fibrillation
- Treatment and prevention of DVT/PE
- VTE prophylaxis after hip or knee replacement
- Secondary prevention of ACS (with aspirin)
Common Doses
AF: 20 mg OD with food (15 mg OD if CrCl 15-49); VTE: 15 mg BD for 21 days then 20 mg OD
Route
Oral
Onset & Duration
Onset 2-4 hours; half-life 5-9 hours (longer in elderly)
Key Differences
| Category | Apixaban | Rivaroxaban |
|---|---|---|
| Dosing frequency | Twice daily | Once daily |
| Major bleeding risk | Lower (ARISTOTLE: HR 0.69 vs warfarin) | Similar to warfarin; higher GI bleeding |
| Food requirement | Can be taken with or without food | Must be taken with food for adequate absorption |
| Renal clearance | 27% renally cleared — preferred in CKD | 36% renally cleared |
| ACS indication | Not licensed for ACS | Licensed for secondary prevention post-ACS |
| Dose reduction criteria | Age >=80 + weight <=60 kg + Cr >=133 (need 2 of 3) | CrCl 15-49 mL/min: reduce to 15 mg OD |
Dosing frequency
Twice daily
Once daily
Major bleeding risk
Lower (ARISTOTLE: HR 0.69 vs warfarin)
Similar to warfarin; higher GI bleeding
Food requirement
Can be taken with or without food
Must be taken with food for adequate absorption
Renal clearance
27% renally cleared — preferred in CKD
36% renally cleared
ACS indication
Not licensed for ACS
Licensed for secondary prevention post-ACS
Dose reduction criteria
Age >=80 + weight <=60 kg + Cr >=133 (need 2 of 3)
CrCl 15-49 mL/min: reduce to 15 mg OD
Key Advantages
Apixaban
- Lowest bleeding rates among DOACs (ARISTOTLE trial)
- Twice-daily dosing provides stable anticoagulation
- No routine monitoring required
- Renal clearance only 27% — safer in moderate renal impairment
Rivaroxaban
- Once-daily dosing improves adherence
- Broader licensed indications (includes ACS)
- Well-established evidence base (ROCKET AF, EINSTEIN trials)
- Can be crushed and given via NG tube
Key Cautions
Apixaban
- Avoid if CrCl <15 mL/min
- Dose reduction criteria: age >=80, weight <=60 kg, creatinine >=133 micromol/L (need 2 of 3)
- No reliable point-of-care monitoring
- Reversal agent: andexanet alfa (limited availability)
Rivaroxaban
- Must be taken with food (bioavailability drops without food)
- Higher GI bleeding rates than apixaban
- Renal clearance 36% — avoid if CrCl <15 mL/min
- Reversal agent: andexanet alfa
Clinical Verdict
Apixaban is generally preferred for AF stroke prevention due to lower bleeding risk and flexible food requirements. Rivaroxaban is a reasonable alternative when once-daily dosing is important for adherence, or in the ACS setting.
Medical Disclaimer: This comparison is for educational purposes only and is not a substitute for professional medical advice. Always consult a qualified healthcare professional before making prescribing decisions. Verify all drug information with current clinical guidelines (BNF, NICE, SmPCs).
Full monographs for Apixaban & Rivaroxaban in the MedNext app
Complete dosing, interactions, contraindications, side effects, and more — covering 2,866 drugs with AI-powered search.
Download MedNext Formulary